The use of specific monoclonal antibodies to target immunogenic tumor membrane proteins in patients with recurrent pancreatic and colon cancer

Current Drug Delivery

Volumn 9, Issue 1, 2012, Pages 52-56

  Arlen, Myron ^a,b   Wang, XuePing ^b   Luka, Janos ^b   Gupta, Rishab ^b   Saric, Olga ^b   Arlen, Philip M ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b Neogenix Oncology   (United States)

Author keywords

ADCC; Immunogenic membrane proteins; Immunotherapy; Monoclonal antibodies; Pancreatic and colon cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ENSITUXIMAB; IMMUNOGLOBULIN G1; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 31.1; MONOCLONAL ANTIBODY NPC 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL ANIMAL; HUMAN; HYBRIDOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 83455212521     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112798376087     Document Type: Article

References (13)

1. Hollinshead, A.; Elias, E.G.; Arlen, M.; Buda, B.; Mosley, M.; Scherrer, J. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer, 1985, 56(3), 480-489.
2. Takita, H.; Hollinshead, A.C.; Adler, R.H.; Bhayana, J.; Ramundo, M.; Moskowitz, R.; Rao, U.N.; Raman, S. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5 years survival analysis. J. Surg. Oncol., 1991, 46(1), 9-14.
3. Arlen, M.; Tsang, K. The nature of the monoclonal antibodies derived from immunogenic membrane antigens of human colon carcinoma origin. J. Tumor. Marker. Oncol., 1990, 5, 313-319.
4. Arlen, P.M.; Kantor, J.; Luka, J.; Saric, O.; Gupta, R.; Arlen, M.; Bristol, A. Preclinical development of a novel therapeutic antibody to treat pancreas and colorectal cancers. Mol. Cancer Ther, 2009, 8 (12 Suppl), B124.
5. Arlen, M.; Arlen, P.; Tsang, A.; Wang, X.; Gupta, R. The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins. J. Cancer, 2010, 1, 209-222.
6. Giantonio, B.J.; Levy, D.E.; O'dwyer, P.J.; Meropol, N.J.; Catalano, P.J.; Benson, A.B. 3rd; Eastern Cooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann. Oncol., 2006, 17(9),1399-1403.
7. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
8. Pietras, R.J.; Fendly, B.M.; Chazin, V.R.; Pegram, M.D.; Howell, S.B.; Slamon, D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 1994, 9(7), 1829-1838.
9. Pietras, R.J.; Arboleda, J.; Reese, D.M.; Wongvipat, N.; Pegram, M.D.; Ramos, L.; Gorman, C.M.; Parker, M.G.; Sliwkowski, M.X.; Slamon, D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growth in human breast cancer cells. Rec. Oncogene, 1995, 10(12), 2435-2446.
10. Shepard, H.M.; Lewis, G.D.; Sarup, J.C.; Fendly, B.M.; Maneval, D.; Mordenti, J.; Figari, I.; Kotts, C.E.; Palladino, M.A. Jr; Ullrich, A. Monoclonal antibody therapy of human cancer: taking the HER-2 proto-oncogene to the clinic. J. Clin. Immunol., 1991, 11(3),117-127.
11. Taylor, C.; Hershman, D.; Shah, N.; Suciu-Foca, N.; Petrylak, D.P.; Taub, R.; Vahdat, L.; Cheng, B.; Pegram, M.; Knutson, K.L.; Clynes, R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res., 2007, 13(17), 5133-5143.
12. Pegram, M.D.; Konecny, G.E.; O'Callaghan, C.; Beryt, M.; Pietras, R.; Slamon, D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst., 2004, 96(10), 739-749.
13. Madan, R.; Arlen, P.M.; Gulley, J.L. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin. Biol. Ther., 2007, 7(4),543-554.